On August 12, 2025, Henderson Jane, the director of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 3,000 shares of the company’s common stock at about $47.46 each. This transaction leaves her with 9,398 shares. Akero Therapeutics is a company in the Medical sector, which includes 979 individual stocks and ranks #8 in the Zacks Sector Rank.
Akero Therapeutics is being closely watched to see if it is outperforming its peers in the Medical sector. The Zacks Sector Rank evaluates sectors based on the average Zacks Rank of individual stocks, aiming to identify those with the potential to outperform the market in the short term. Akero’s performance is compared to Aveanna Healthcare (AVAH) and the broader sector to assess its relative success.
The current stock price of AKRO is $48.03, reflecting a decrease of $0.25, or approximately -0.52% in percentage terms. Today, the stock has traded between $47.10 and $48.80. Over the past year, AKRO has reached a high of $58.40 and a low of $21.34. The company’s market capitalization is approximately $3.84 billion. Today’s trading volume for AKRO is 880,811 shares on the NASDAQ exchange. This volume indicates the level of investor interest and activity in the stock. Despite the recent sale by Henderson Jane, the stock’s performance and trading activity continue to be of interest to investors and analysts alike.
